$194 Million is the total value of Prosight Management, LP's 35 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 59.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HNGR | Sell | HANGER INC | $22,539,000 | -9.8% | 1,189,399 | -0.9% | 11.64% | -16.5% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $14,193,000 | +116.6% | 253,000 | +215.6% | 7.33% | +100.5% |
| CI | New | CIGNA CORP NEW | $13,921,000 | – | 73,300 | +100.0% | 7.19% | – |
| WCG | New | WELLCARE HEALTH PLANS INC | $11,805,000 | – | 50,000 | +100.0% | 6.09% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $10,814,000 | -3.7% | 277,650 | +13.8% | 5.58% | -10.8% |
| ZBH | Buy | ZIMMER BIOMET HLDGS INC | $10,723,000 | +27.6% | 103,380 | +61.7% | 5.54% | +18.1% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $9,403,000 | +16.9% | 1,062,500 | +48.5% | 4.85% | +8.2% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $8,770,000 | -6.2% | 103,000 | +6.8% | 4.53% | -13.2% |
| AGN | Buy | ALLERGAN PLC | $8,207,000 | +37.2% | 61,400 | +95.5% | 4.24% | +27.0% |
| ALBO | Buy | ALBIREO PHARMA INC | $6,627,000 | +23.4% | 270,146 | +65.8% | 3.42% | +14.3% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $6,242,000 | +40.6% | 275,941 | +130.8% | 3.22% | +30.2% |
| GLPG | New | GALAPAGOS NVspon adr | $5,766,000 | – | 62,850 | +100.0% | 2.98% | – |
| Sell | INTEC PHARMA LTD JERUSALEM | $5,098,000 | -32.5% | 676,104 | -49.4% | 2.63% | -37.5% | |
| TLGT | Buy | TELIGENT INC NEW | $4,860,000 | -62.0% | 3,547,607 | +9.5% | 2.51% | -64.9% |
| ASGN | New | ASGN INC | $4,780,000 | – | 87,700 | +100.0% | 2.47% | – |
| VKTX | Buy | VIKING THERAPEUTICS INC | $4,774,000 | -0.1% | 624,000 | +127.4% | 2.46% | -7.5% |
| PRSC | Sell | PROVIDENCE SVC CORP | $4,699,000 | -18.0% | 78,298 | -8.1% | 2.43% | -24.1% |
| KURA | Buy | KURA ONCOLOGY INC | $4,445,000 | +0.1% | 316,581 | +24.8% | 2.30% | -7.3% |
| AXGN | Buy | AXOGEN INC | $4,272,000 | +51.1% | 209,088 | +172.5% | 2.20% | +39.8% |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $4,202,000 | +104.4% | 937,900 | +121.3% | 2.17% | +89.3% |
| CBIO | Buy | CATALYST BIOSCIENCES INC | $3,684,000 | +44.5% | 466,900 | +97.4% | 1.90% | +33.8% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $3,371,000 | -27.1% | 2,553,943 | -6.1% | 1.74% | -32.5% |
| ALDX | New | ALDEYRA THERAPEUTICS INC | $3,357,000 | – | 404,463 | +100.0% | 1.73% | – |
| CNC | Buy | CENTENE CORP DEL | $2,883,000 | +0.2% | 25,000 | +25.8% | 1.49% | -7.3% |
| MGNX | Sell | MACROGENICS INC | $2,465,000 | -74.9% | 194,129 | -57.6% | 1.27% | -76.7% |
| EOLS | Buy | EVOLUS INC | $2,331,000 | -9.6% | 195,911 | +41.5% | 1.20% | -16.3% |
| MLND | New | MILLENDO THERAPEUTICS INC | $2,041,000 | – | 256,739 | +100.0% | 1.05% | – |
| LGND | New | LIGAND PHARMACEUTICALS INC | $1,710,000 | – | 12,600 | +100.0% | 0.88% | – |
| GTS | New | TRIPLE-S MGMT CORPcl b | $1,139,000 | – | 65,515 | +100.0% | 0.59% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $1,079,000 | – | 60,100 | +100.0% | 0.56% | – |
| CERC | New | CERECOR INC | $994,000 | – | 307,733 | +100.0% | 0.51% | – |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $885,000 | -90.5% | 332,846 | -80.0% | 0.46% | -91.2% |
| OPTN | New | OPTINOSE INC | $870,000 | – | 140,314 | +100.0% | 0.45% | – |
| CDTX | Sell | CIDARA THERAPEUTICS INC | $578,000 | -59.6% | 245,764 | -24.4% | 0.30% | -62.6% |
| AQXP | Buy | AQUINOX PHARMACEUTICALS INC | $173,000 | +4.2% | 80,289 | +41.7% | 0.09% | -4.3% |
| MGTX | Exit | MEIRAGTX HOLDINGS PLC | $0 | – | -38,746 | -100.0% | -0.29% | – |
| OVAS | Exit | OVASCIENCE INC | $0 | – | -1,529,700 | -100.0% | -0.62% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -52,331 | -100.0% | -0.62% | – |
| NVLNF | Exit | NOVELION THERAPEUTICS INC | $0 | – | -444,068 | -100.0% | -0.73% | – |
| Exit | RETROPHIN INCput | $0 | – | -102,300 | -100.0% | -1.64% | – | |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -341,457 | -100.0% | -2.28% | – |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -23,400 | -100.0% | -2.36% | – |
| CI | Exit | CIGNA CORPORATION | $0 | – | -29,236 | -100.0% | -3.40% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.